Division/School Bristol Medical School
Contract type Fixed Term Contract
Working pattern Full time
Salary £32,000 per annum
Closing date for applications 22-Sep-2019

Based at UCB Celltech in Slough, this post is funded through a Knowledge Transfer Partnership between the University of Bristol and UCB Celltech.

You will be at the heart of an exciting collaboration between UCB Celltech and Translational Health Sciences at the University of Bristol. The collaboration aims to develop a multicellular model of human Glomerulosclerosis into a medium throughput, highly quality controlled platform for drug screening of anti fibrotic molecules and stratifying patients for suitability into clinical trials.

Your role will be to adapt the existing disease model into a tool and incorporate it into UCB’s high throughput screening platform, by optimising and automating key steps in the protocol. This will involve using human glomerular cell lines available within Bristol Renal to form a physiologically relevant glomerular 3D spheroid model that represents that seen in vivo. There are a number of technical challenges associated with achieving this, and you will lead on addressing these. You will also need to elucidate how the disease model can be incorporated into and operate within UCB’s drug discovery platform, which currently uses models that are significantly different from this one. This capability will be an industry first which will enable the discovery of new, more effective pharmaceuticals that will improve patient outcomes worldwide.

You will be mainly based at UCB Celltech in Slough, but you will also spend some time at Bristol Medical School to carry out some of the research work, and to interact with researchers working in this space.

Interviews are expected to be held early October 2019.

For informal enquiries, please contact: Dr Gavin Welsh G.I.Welsh@bristol.ac.uk, Tel (0117) 331 3086.

We welcome applications from all members of our community and are particularly encouraging those from diverse groups, such as members of the LGBT+ and BAME communities, to join us.